行情

NBY

NBY

Novabay制药
AMEX

实时行情|Nasdaq Last Sale

0.7160
+0.0072
+1.02%
盘后: 0.7200 +0.004 +0.56% 19:50 06/18 EDT
开盘
0.7074
昨收
0.7088
最高
0.8772
最低
0.7000
成交量
564.18万
成交额
--
52周最高
1.940
52周最低
0.5150
市值
3,003.09万
市盈率(TTM)
-2.3429
分时
5日
1月
3月
1年
5年
BRIEF-NovaBay Pharmaceuticals - Notified By FDA That It Declines To Review Co's EUA Request For Sars-Cov-2 IGG & IGM Antibody Combined Test Kits
reuters.com · 06/11 21:18
Axios 报告显示 Covid-19 阳性率在总是戴口罩的人中最低
https://www.axios.com/coronavirus-masks-fewer-positive-tests-87a97b0f-6d30-4440-a16f-ef73bb859c2b.html
Benzinga · 06/07 09:27
纽约州教育部表示口罩规定仍然有效
https://abc7ny.com/10751908/?ex_cid=TA_WABC_FB&taid=60bd51b4ba52ee00010b84f1&utm_campaign=trueAnthem:+New+Content+(Feed)&utm_medium=trueAnthem&utm_source=facebook
Benzinga · 06/06 22:54
克罗格说,到5月20日,接受全面疫苗接种的客户,大多数经过全面疫苗接种的员工将不再需要在公司的商店中佩戴口罩。
-Reuters
Reuters · 05/19 17:05
Brief-Novabay Pharmaceuticals宣布在亚马逊上提供I-Chek照明眼科检查镜
reuters.com · 05/17 10:56
Brief-Novabay Pharmaceuticals提交4月2日的招股说明书补充招股说明书签署了一项ATM发行协议,以出售高达400万美元的股票
reuters.com · 05/14 22:44
继美联社报道后,关注个人防护设备制造商,Alpha Pro Tech,Novabay CDC会说接受COVID-19疫苗接种的人不需要经常在室内戴口罩
-Bloomberg
Bloomberg · 05/13 17:04
Brief-Novabay Pharmaceuticals报告2021年第一季度财务业绩
reuters.com · 05/06 20:38
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解NBY最新的财务预测,通过NBY每股收益,每股净资产,每股现金流等数据分析Novabay制药近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测NBY价格均价为2.575,最高价位3.250,最低价为1.900。
EPS
机构持股
总机构数: 20
机构持股: 64.76万
持股比例: 1.54%
总股本: 4,194.26万
类型机构数股数
增持
3
38.36万
建仓
7
17.45万
减持
6
9.77万
平仓
2
1.24万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.57%
制药与医学研究
-0.98%
高管信息
Non-Executive Chairman/Independent Director
Paul Freiman
President/Chief Executive Officer/Director/IR Contact Officer
Justin Hall
Chief Financial Officer/Treasurer
Andrew Jones
Controller
Wang Xu
Director
Xinzhou Li
Director
Mijia Wu
Independent Director
Swan Sit
Independent Director
Yenyou Zheng
暂无数据
NBY 简况
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

微牛提供NovaBay Pharmaceuticals, Inc.(AMEX-NBY)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NBY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NBY股票基本功能。